Verily and Samsung Collaborate to Advance Clinical Trials with Smartwatch Data Integration

The landscape of clinical trials is evolving rapidly with the integration of modern wearable technology, and a recent partnership between Verily and Samsung exemplifies this trend. Announced in early March 2026, Verily and Samsung have teamed up to bring Galaxy smartwatch data directly into Verily's Pre platform, creating a streamlined system for pharmaceutical researchers to harness continuous, real-world health data collected from patients remotely during clinical trials.

Background and Collaboration Overview

Verily, known for its focus on healthcare data science and technology, and Samsung, a leading global provider of wearable devices, announced that the partnership aims to develop an end-to-end solution for the deployment and management of wearable devices in clinical studies. This collaboration intends to advance the capabilities of Verily's digital health platform by incorporating the comprehensive biometric data generated by Samsung’s Galaxy smartwatches.

Purpose of the Partnership

The primary objective of integrating Galaxy smartwatch data into clinical trials is to enhance the accuracy and depth of patient monitoring. Traditional clinical trial methods rely heavily on periodic in-clinic visits and self-reported patient outcomes, which can miss important fluctuations and events in patients’ health status. By leveraging continuous data streams from wearables, researchers aim to:

Monitor patients remotely in real-time, reducing burdensome clinic visits.
Capture detailed physiological metrics such as heart rate, physical activity, sleep patterns, and possibly other biosignals.
Improve patient engagement and adherence through digital tools.
Enable the early detection of adverse events or health changes during trials.

How the Integration Works

Verily’s Pre platform serves as a data aggregation and analysis tool tailored for pharmaceutical trials. The integration process involves Samsung’s smartwatches securely transmitting collected health data to the Pre platform. This system enables seamless data collection, encrypted data storage, and sophisticated analytical capabilities to interpret health signals over the course of a study.

Pharma researchers will be able to configure deployment of the smartwatches to trial participants, remotely track data quality and patient compliance, and run data analyses to identify clinically relevant patterns. This approach supports adaptive trial designs and more nuanced understanding of treatment effects.

Potential Impact on Pharmaceutical Research

This partnership heralds a new era where digital health technologies are embedded into clinical research workflows. Some significant implications include:

Accelerated Data Collection: Continuous monitoring accelerates data acquisition compared to sporadic clinical measurements.
Enhanced Data Quality: Objective digital biomarkers may reduce reliance on subjective outcomes, minimizing reporting biases.
Patient-Centric Trials: Remote monitoring can reduce participant burden and widen access to trials, enhancing diversity in patient populations.
Improved Outcome Measures: Integration of passive monitoring data offers new endpoints beyond traditional clinical assessments.
Cost Efficiency: Remote data collection can reduce site visits and related costs.

Challenges and Considerations

While promising, the integration of wearable data into clinical research poses challenges. Regulatory acceptance of novel digital endpoints remains under development. Data privacy and security are paramount concerns requiring robust protections. Additionally, ensuring interoperability and standardization across devices and platforms is critical for scalable adoption.

Stakeholders will closely observe how this partnership addresses these challenges and how the FDA and other regulatory agencies respond to data derived from consumer-grade devices in clinical evidence generation.

Industry Context

Verily and Samsung join a growing ecosystem of technology and pharmaceutical companies exploring digital health integration. The pandemic accelerated acceptance of decentralized trial elements, and wearables are now central to this transformation. This collaboration is a leading example signaling broader shifts in clinical trial methodology driven by digital innovation.

Conclusion

Verily and Samsung’s partnership to bring Galaxy smartwatch data into clinical trials represents a meaningful advance in leveraging consumer technology for medical research. By combining Verily’s data science expertise with Samsung’s wearable hardware, the initiative offers a blueprint for more efficient, patient-friendly, and data-rich clinical trials. As this model evolves, it holds potential to reshape drug development paradigms and accelerate the delivery of novel therapies to patients worldwide.

For further details, see the original announcement: Verily & Samsung Team Up to Bring Smartwatch Data into Clinical Trials.

This article is independent and analyzed objectively, based on the announcement and current trends in medical technology.